These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 186092)

  • 61. [Bile acids in the serum of patients with extrahepatic cholestasis with chronic liver diseases].
    Erb W; Schreiber J; Walczak M
    Z Gastroenterol; 1973 May; 11(4):279-88. PubMed ID: 4803425
    [No Abstract]   [Full Text] [Related]  

  • 62. [Properties of 2 fibrin monomer species which differ in the degree of thrombin activation. Characteristics of successively appearing active sites].
    Lugovskoĭ EV; Gogolinskaia GK; Derzskaia SG; Belitser VA
    Biokhimiia; 1978 Jun; 43(6):1045-53. PubMed ID: 667211
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Fibrinogen anomalies and disease. A clinical update.
    Galanakis DK
    Hematol Oncol Clin North Am; 1992 Oct; 6(5):1171-87. PubMed ID: 1400080
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A study of impaired fibrin polymerization in patients with the nephrotic syndrome.
    Mysliwiec M; Ralston A; Ackrill P; Poller L
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(1):73-8. PubMed ID: 1695187
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Reptilase time in cirrhosis and hepatocellular carcinoma.
    Johnson PJ; White Y; Woolf IL; Williams R
    Br Med J; 1977 Oct; 2(6091):869-70. PubMed ID: 200301
    [No Abstract]   [Full Text] [Related]  

  • 66. A hereditary dysfibrinogenemia: fibrinogen Awaji.
    Matsuo T; Okuno S; Mukaida T; Ueshima S; Okada K; Matsuo O
    Haemostasis; 1987; 17(1-2):89-97. PubMed ID: 3596361
    [TBL] [Abstract][Full Text] [Related]  

  • 67. "Fibrinogen Tokyo II". An abnormal fibrinogen with an impaired polymerization site on the aligned DD domain of fibrin molecules.
    Matsuda M; Baba M; Morimoto K; Nakamikawa C
    J Clin Invest; 1983 Sep; 72(3):1034-41. PubMed ID: 6886002
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Fibrinogen Milano II: a congenital dysfibrinogenaemia associated with juvenile arterial and venous thrombosis.
    Haverkate F; Koopman J; Kluft C; D'Angelo A; Cattaneo M; Mannucci PM
    Thromb Haemost; 1986 Feb; 55(1):131-5. PubMed ID: 3705000
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Fibrinogen Vicenza and Genova II: two new cases of congenital dysfibrinogenemia with isolated defect of fibrin monomer polymerization and inhibitory activity on normal coagulation.
    Rodeghiero F; Castaman GC; Dal Belin Peruffo A; Dini E; Galletti A; Barone E; Gastaldi G
    Thromb Haemost; 1987 Jun; 57(3):252-8. PubMed ID: 2958952
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Dysfibrinogen Kagoshima with the amino acid substitution gammaThr-314 to Ile: analyses of molecular abnormalities and thrombophilic nature of this abnormal molecule.
    Niwa K; Mimuro J; Miyata M; Sugo T; Ohmori T; Madoiwa S; Tei C; Sakata Y
    Thromb Res; 2008; 121(6):773-80. PubMed ID: 17854865
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Evidence that catalytically-inactivated thrombin forms non-covalently linked dimers that bridge between fibrin/fibrinogen fibers and enhance fibrin polymerization.
    Mosesson MW; Hernandez I; Siebenlist KR
    Biophys Chem; 2004 Jul; 110(1-2):93-100. PubMed ID: 15223147
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Dysfibrinogenaemia and primary hepato-cellular carcinoma.
    Barr RD; Ouna N; Simpson JG; Bagshawe AF
    Q J Med; 1976 Oct; 45(180):647-59. PubMed ID: 188064
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Intraperitoneal coagulation in chronic liver disease ascites.
    Hoefs J; Barnes T; Halle P
    Dig Dis Sci; 1981 Jun; 26(6):518-22. PubMed ID: 7238271
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Significance of intravascular coagulation and fibrinolysis in acute hepatic failure.
    Hillenbrand P; Parbhoo SP; Jedrychowski A; Sherlock S
    Gut; 1974 Feb; 15(2):83-8. PubMed ID: 4820641
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Recombinant γT305A fibrinogen indicates severely impaired fibrin polymerization due to the aberrant function of hole 'A' and calcium binding sites.
    Ikeda M; Kobayashi T; Arai S; Mukai S; Takezawa Y; Terasawa F; Okumura N
    Thromb Res; 2014 Aug; 134(2):518-25. PubMed ID: 24968960
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Functional and metabolic properties of human asialofibrinogen.
    Martinez J; Palascak J; Peters C
    J Lab Clin Med; 1977 Feb; 89(2):367-77. PubMed ID: 833473
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Impaired metabolism of methionine in severe liver diseases. I. Clinical and pathophysiological significance of elevated serum methionine levels.
    Higashi T
    Gastroenterol Jpn; 1982 Apr; 17(2):117-24. PubMed ID: 6286400
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Crosslinking of fibrinogen to immobilized DesAA-fibrin.
    Selmayr E; Thiel W; Müller-Berghaus G
    Thromb Res; 1985 Aug; 39(4):459-65. PubMed ID: 4049326
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Changes in the carbohydrate composition of fibrinogen in cases of acquired dysfibrinogenemia].
    Mester L; Szabados L; Soria J
    C R Acad Hebd Seances Acad Sci D; 1970 Nov; 271(20):1813-5. PubMed ID: 4322244
    [No Abstract]   [Full Text] [Related]  

  • 80. Ceruloplasmin activity in liver diseases quantitative determination and electrophoretic characterization.
    Secchi GC; Petrella A; Lomanto B; Gervasini N
    Enzymol Biol Clin (Basel); 1967; 8(1):33-41. PubMed ID: 6030815
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.